Building fellowships in male andrology and broader men’s health is becoming a key role in training younger physicians in the field for men’s health clinics. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comprehensive health care for men.
Urologists and internists who direct successful comprehensive men’s health centers in the U.S. say these centers need to do more than cater to men’s health needs. They should also cater to men’s wants. Specifically, here are three design elements you should incorporate into your men’s health center, if you haven’t done so already.
Multidisciplinary men’s health centers, rooted at hospitals, academic centers, and some private clinics, have expanded in the last few years and are meeting an important need in medicine, say key figures in these centers. Urologists are helping to drive these clinics’ success.
Men’s health clinics are a growing trend centered around the global care of men and the philosophy that men need to be taken care of in a holistic way. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comphrensive health care for men.
Leaders of state, national, and subspecialty urologic societies from around the country converged in Rosemont, IL in September for a weekend of health policy discussions and advocacy tips with public officials, policy experts, and fellow urologists. One of the themes reinforced at the 7th Annual State Society Network Advocacy Conference, hosted by the AACU, was the importance and impact of physician engagement in the political process.
The AUA has updated its guideline on interstitial cystitis/bladder pain syndrome, with changes primarily focusing on aspects of treatment for a condition that affects three to eight million women and one to four million men in the United States.
Abiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 clinical trial.
Take a tour of Iris Cantor Men’s Health Center at NewYork-Presbyterian/Weill Cornell with this slideshow.
The AUA’s Committee on Male Health has developed a checklist to serve as a resource of urologic and non-urologic men’s health considerations. Intended for urologists and other health care providers, it is also aimed at better coordinating care among men’s providers.
Drugs and devices in the pipeline from Repros Therapeutics, Bavarian Nordic, NxThera, Solace Therapeutics, Generex Biotechnology, Bioniche, OncoCyte, HistoSonics, and Pacific Edge.
Urology Times is committed to the men’s health trend and to helping you make the most of it, UT Group Content Director Richard R. Kerr writes.
The effect of the U.S. Preventive Services Task Force’s controversial grade “D” recommendation regarding PSA-based screening for prostate cancer “has been minimal at best,” according to a research letter that also shows a “shocking” level of statewide variance in screening, a leading prostate cancer expert said.
The ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective Nov. 3, 2014, MDxHealth SA announced, while the maker of a second test, the Decipher Prostate Cancer Classifier, has added a new preferred provider organization to expand coverage of that test.
Results of a study analyzing data from the Surveillance, Epidemiology, and End Results program add to evidence of race-related disparity in receipt of treatment for prostate cancer, but show that having health insurance reduces the difference in care.
Results of a phase II study from the Prostate Cancer Clinical Trials Consortium show that abiraterone acetate (ZYTIGA) has modest clinical activity in men with progressive metastatic castrate-resistant prostate cancer previously treated with ketoconazole.
In patients with recurrent bladder neck contractures, history often repeats itself with multiple surgeries and poor outcomes, but reconstructive urologists are now hopeful they have a better solution.
Inappropriate use of a gonadotropin-releasing hormone agonist for androgen deprivation therapy of localized prostate cancer fell dramatically following implementation of reimbursement cuts mandated by the Medicare Modernization Act of 2003, but overuse remains problematic, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
Other cases discussed in this installment of "Malpractice Consult" include chronic testicular pain following vasectomy and a claim that a spinal tumor should have been found during treatment for post-vasectomy urinary problems.
In this "Coding Q&A" column, Ray Painter, MD, and Mark Painter answer several reader questions involving billing for multiple stones, including replacements for the –59 modifier, use of CPT code 50590, and NCCI guidelines and multiple stones.
In this article, Robert A. Dowling, MD, discusses what you need to know about EHRs and patient safety.
In light the controversial studies linking testosterone replacement therapy to cardiovascular risks, three urologists discuss how their approach to prescribing TRT has (or hasn't) changed.
In this interview, Ian Thompson, MD, answers questions about the downside of diagnosing low-risk prostate cancer, the burdens of active surveillance and how to minimize them, and how his own approach to screening and biopsy have changed.
Ultrasound should be the initial diagnostic imaging test utilized for diagnosing kidney stones in order to reduce the higher radiation exposure associated with computed tomography, say the authors of a recent study.
The Decipher Prostate Cancer Classifier test predicts disease aggressiveness, influences treatment decisions, and predicts which patients may benefit from post-prostatectomy radiation therapy, according to findings from three studies presented at the American Society for Radiation Oncology annual meeting in San Francisco.
An FDA advisory committee has voted to restrict indications for testosterone replacement therapy and require additional clinical trials to test the safety of the drugs, decisions that have drawn mixed reactions from urologists.
When faced with the difficult prospect of changing one’s normal style of living, the major factors to consider are age, interests, finances, and of course, health issues and concerns.
In this article, Ahmed A. Hussein, MD, and James F. Smith, MD, MS, examine the effect of malignancy and anti-cancer treatment on fertility, review current fertility preservation methods, and offer a preview of fertility preservation techniques that hold future promise.
The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.
The month of September has seen two notable appointments in academic urology, with David F. Penson, MD, MPH, and James McKiernan, MD, both named to department chair positions.
I was driving home from the office last week and realized that I have now been in the "real world" for over a year. As I looked back on the last year, I thought I would share a few of the lessons I've learned as I am curious if others have had a similar experience during their transition from residency to private practice.